CARDIO-TTRansform Magnetic Resonance Imaging (MRI) Sub-study
Running, not enrolling
Conditions studied: Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
In brief
The main purpose of this study is to measure the amyloid burden, defined as extracellular volume (ECV) assessed by Magnetic Resonance Imaging (MRI) over time in a subset of up to 150 participants enrolled in ION-682884-CS2 (NCT04136171).
Key facts
- Study ID
- NCT06073574
- Run by
- Ionis Pharmaceuticals, Inc.
- People needed
- 150
- Starts
- 2021-03-31
- Expected to finish
- 2026-04-01
- Last updated by the study team
- 2025-11-28
Who can join
Age: 18 and older, up to 90. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- To participate in the ION-682884-CS2MRI sub-study, participants must meet all inclusion criteria of the study protocol ION-682884-CS2 (NCT04136171).
You may not qualify if…
- Contraindication or sensitivity to MRI contrast agents
- Orthopnea of sufficient severity to preclude supine scanning at screening.
- Weight or body girth exceeds the limits of the cardiac MRI machine specifications.
- Contraindication to cardiac MRI scanning, as assessed by local MRI safety questionnaire/checklist.
Where it is running
- Brigham and Women's Hospital — Boston, Massachusetts, United States
- Oregon Health and Science University — Portland, Oregon, United States
- Azienda Ospedaliero - Universitaria Careggi — Florence, Italy
- Azienda Ospedale Università di Padova — Padova, Italy
- Hospital Universitario Puerta de Hierro — Majadahonda, Spain
- Synexus - Scotland Clinical Research Centre — Bellshill, United Kingdom
- Synexus Midlands Clinical Research Centre — Birmingham, United Kingdom
- Synexus - Wales — Cardiff, United Kingdom
- Royal Free London NHS Foundation Trust — London, United Kingdom
- Richmond Pharmacology — London, United Kingdom
- Synexus - Manchester Clinical Research Centre — Manchester, United Kingdom
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.